Contineum Therapeutics, Inc.
CTNM
$9.80
-$0.59-5.68%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -78.04% | -89.97% | -87.48% | -64.25% | -121.68% |
| Total Depreciation and Amortization | 31.67% | 27.87% | 102.70% | 44.19% | 42.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 239.00% | 2,335.85% | 835.16% | 696.53% | 125.67% |
| Change in Net Operating Assets | -825.36% | -493.45% | 205.73% | 107.15% | -112.58% |
| Cash from Operations | -84.27% | -80.71% | 4.69% | -14.73% | -120.90% |
| Capital Expenditure | 63.03% | 68.03% | 46.28% | -272.73% | -283.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 135.92% | 68.53% | -198.75% | 23.69% | 12.71% |
| Cash from Investing | 135.69% | 70.83% | -203.96% | 23.58% | 12.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.75% | -80.33% | 1,184.00% | -84.15% | 569,500.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -225.71% | -- | -- | -- | -- |
| Cash from Financing | -99.92% | 233.33% | 300.00% | -99.87% | 131.60% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -102.77% | -28.59% | -849.77% | -5.18% | 41.76% |